NEW SILKROUTES GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199400571K)

INCORPORATION OF INDIRECT SUBSIDIARY, SUPPLEMENTAL LETTERS AND COMPLETION OF THE PROPOSED ACQUISITIONS OF CERTAIN DENTAL COMPANIES

---

1. The board of directors (the "**Board**" or the "**Directors**") of New Silkroutes Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to its announcement dated 29 May 2017 relating to the Proposed Acquisitions.

   Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meanings as defined in the announcement dated 29 May 2017.

Incorporation of Indirect Subsidiary

2. The Board wishes to announce that its 51%-owned subsidiary, Healthsciences International Pte. Ltd., has on 28 June 2017 incorporated a private company limited by shares in Singapore named HSI Nominees A Pte. Ltd. ("**HSI Nominees**") to be its wholly-owned subsidiary. HSI Nominees is an investment holding company.

   The incorporation of HSI Nominees was funded through the Company's internal resources and is not expected to have any material impact on the net earnings per share or the net tangible assets per share of the Company for the current financial year ending 30 June 2017.

Supplemental Letters

3. The Board wishes to announce that the Company and Healthsciences International Pte. Ltd. have entered into supplemental letters dated 30 June 2017 with each of the Vendors pursuant to which the parties agreed that HSI Nominees shall replace Healthsciences International Pte. Ltd. as the "Purchaser" in the SPAs. In addition, the following amendments were made to the SPAs with Dr Liew and Dr Kee:

   (i) instead of S$1,200,000.00, the consideration payable to Dr Liew shall be S$1,060,000.00; and

   (ii) instead of S$3,000,000.00, the consideration payable to Dr Kee shall be S$2,650,000.00.

Completion and Issue and Allotment of Consideration Shares and Consultant Shares

4. The Board is pleased to announce that the Proposed Acquisitions were completed today.

5. Following the completion of the Proposed Acquisitions, each of the Trendz Companies and each of the Orange Companies have become indirectly-owned subsidiaries of the Company. The Company owns 51% of the shares in Healthsciences International Pte. Ltd., which in turn owns 100% of the shares in HSI Nominees, which in turn owns 70% of the shares in each of the Trendz Companies and 51% of the shares in each of the Orange Companies.

6. The Board also wishes to announce that the Company has today issued and allotted the Consideration Shares to the Vendors and/or the nominees notified by the Vendors in the following manner and proportion:

Allottee	Consideration Shares
Dr Liew	976,700

Dr Kee	3,360,508
Dr Seow Kok Siam, Joseph (as nominee of Dr Liew)	612,506
Dr Seow Kok Siam, Joseph (as nominee of Dr Kee)	612,506
Dr Wong	1,619,191

7. In addition, the Company has today issued and allotted the Consultant Shares to the Consultants in the following manner and proportion:

Allottee	**Consideration Shares**
Mr Ling	82,579
Dr Liew (as nominee of Nest Capital)	55,053

8. Pursuant to the issue and allotment of the Consideration Shares and the Consultant Shares, the total number of issued and paid-up ordinary shares in the Company has increased from 137,244,144 to 144,563,187 shares. The Consideration Shares and the Consultant Shares rank *pari passu* in all respects with and carry all rights similar to the existing issued and paid-up ordinary shares in the capital of the Company as at the date of issue and allotment of the Consideration Shares and the Consultant Shares, save for any entitlements, distributions, dividends or rights (if any), the record date of which falls prior to the date of issue of the Consideration Shares and Consultant Shares.

9. The Consideration Shares and the Consultant Shares will be listed and quoted on the SGX-ST with effect from 9.00 a.m. on 5 July 2017.

BY ORDER OF THE BOARD

Lim Koon Hock
Joint Company Secretary
30 June 2017